MedTrace Logo

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01281631 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2012-11-22

No results posted yet for this study

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.

Conditions

Interventions

DRUG

NP001

Low dose of NP001

DRUG

NP001

High dose of NP001

DRUG

Placebo

normal saline

Sponsors & Collaborators

  • Neuraltus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert G. Miller, MD · Forbes Norris ALS Treatment and Research, California Pacific Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281631 on ClinicalTrials.gov